Details for New Drug Application (NDA): 021433
✉ Email this page to a colleague
NDA 021433 describes FLOVENT HFA, which is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug. Additional details are available on the FLOVENT HFA profile page.
The generic ingredient in FLOVENT HFA is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-two suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
The generic ingredient in FLOVENT HFA is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-two suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for 021433
| Tradename: | FLOVENT HFA |
| Applicant: | Glaxo Grp Ltd |
| Ingredient: | fluticasone propionate |
| Patents: | 1 |
Pharmacology for NDA: 021433
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Suppliers and Packaging for NDA: 021433
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433 | NDA | GlaxoSmithKline LLC | 0173-0718 | 0173-0718-20 | 1 INHALER in 1 CARTON (0173-0718-20) / 120 AEROSOL, METERED in 1 INHALER |
| FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433 | NDA | GlaxoSmithKline LLC | 0173-0719 | 0173-0719-20 | 1 INHALER in 1 CARTON (0173-0719-20) / 120 AEROSOL, METERED in 1 INHALER |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.22MG/INH | ||||
| Approval Date: | May 14, 2004 | TE: | RLD: | Yes | |||||
| Patent: | 7,500,444*PED | Patent Expiration: | Aug 26, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.11MG/INH | ||||
| Approval Date: | May 14, 2004 | TE: | RLD: | Yes | |||||
| Patent: | 7,500,444*PED | Patent Expiration: | Aug 26, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.044MG/INH | ||||
| Approval Date: | May 14, 2004 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 021433
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | 6,161,724*PED | ⤷ Subscribe |
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | 6,161,724*PED | ⤷ Subscribe |
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | 5,674,472*PED | ⤷ Subscribe |
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | 6,170,717*PED | ⤷ Subscribe |
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | 6,431,168*PED | ⤷ Subscribe |
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-003 | May 14, 2004 | 6,510,969*PED | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
